Insider filing
Traded Dec 12, 2025 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 24, 2026 · Filed Feb 26, 2026
A Sensus Healthcare director paid $7.6K out of pocket for Sensus Healthcare shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$7,620
Shares × reported transaction price
<$25K
+1.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 3 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
12 days after results of Feb 12, 2026, 72 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $3.84 on Feb 24, 2026, 24% above its 52-week low and 32% below its high, after a 19% drop over the previous 30 trading days
52-week range $3.09 (Sep 17, 2025) to $5.65 (Jul 24, 2025), 29% of the way up, from 251 adjusted closes. 30 trading days earlier: $4.76 on Jan 9, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.4% | −2.0% | +5.4% |
| 30 days | −5.8% | −7.9% | +2.0% |
| 90 days | −22.6% | +10.0% | −32.6% |
| 180 days | −19.9% | +11.7% | −31.6% |
Past results only. Not a forecast.
Insider filing
Traded Dec 12, 2025 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Eric Sachetta, Director's past purchases, 90 days after disclosure: 4 buys, median −10.5 pts vs S&P 500, beat it 0 of 4 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.